Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1997-12-16
2000-02-22
Brusca, John S.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435194, 435371, 435375, 536 231, 536 2431, 536 245, C12Q 168, C12N 900, C12N 1585, C07H 2104
Patent
active
060278927
ABSTRACT:
Provided are antisense oligonucleotides directed against the raf-1 gene, Ha-ras gene and HER-2 gene, components of a signal transduction pathway involving oncogenes and their normal counterparts and leading to the phenotype of cellular radioresistance. Administration of these antisense oligonucleotides is shown to reverse the radioresistance phenotype in cells overexpressing HER-2 or a mutant form of Ha-ras. Methods and compositions for reversing radiation resistance among other conditions involving these genes are disclosed.
REFERENCES:
patent: 5576208 (1996-11-01), Monia et al.
patent: 5599704 (1997-02-01), Thompson et al.
patent: 5734039 (1998-03-01), Calabretta et al.
Denner, Ia et al. (Jul. 21, 1994) WO9415645-A. Database: Geneseq, Q67036 (Accessed Jul. 24, 1998).
Kasid et al. Science, Mar. 10, 1989. vol. 243, pp. 1354-1356.
Daum et al. TIBS 19, 474-480 (Nov. 1994).
Tseng et al. Cancer Gene Therapy. vol 1 (1), pp. 65-71 (Mar. 1994).
Branch, A.D. TIBS 23, 45-50 (Feb. 1998).
Gewirtz et al. PNAS. 93, 3161-3163 (Apr. 1996).
Rojanasakul. Advanced Drug Delivery Review. 18, 115-131 (Jan, 30, 1996).
Maher et al. Archives of Biochemistry and Biophysics. Vol. 253, pp. 214-220 (Feb. 15, 1987).
Gura, T. Science, vol. 278, pp. 1041-1042 (Nov. 1997).
Crooke, S.T. Chapter 1, Basic Principles of Antisense Therapeutics on "Antisense Research And Application" (ed. Stanley T. Crooke), Springer-Verlag, New York, (Jul. 1998) pp. 1-50.
Betram, J., et al., "Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides", (1994) Biochem. Biophys. Res. Commun. 200:661-667.
Bradley, Matthews O., et al., "Reversal of Transformed Phenotypes by Antisense fos", (1992) Annals New York Academy of Sciences, pp. 124-135.
Daum, Gunter, et al., "The ins and outs of Raf kinases", (1994) Trends Biochem. Sci. 19, 474-480.
Dean, N.M., et al., "Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents", (1996) Biochem. Soc. Trans. 24, 623-629.
Kasid, U., et al., "Effect of Antisense c-raf-1 on Tumorigenicity and Radiation Sensitivity of a Human Squamous Carcinoma", (1989) Science 243, 1354-1356.
Kasid, U., et al., "The raf Oncogene is Associated with a Radiation-Resistant Human Laryngeal Cancer", (1987) Science 237, 1039-1041.
Kizaka-Kondoh, Shinae, et al., "Raf-1 Protein Kinase Is an Integral Component of the Oncogenic Signal Cascade Shared by Epidermal Growth Factor and Platelet-Derived Growth Factor", (1992) Mol. Cell. Biol. 12:5078-5086.
Ledwith, Brian J., et al., "Antisense-fos RNA Causes Partial Reversion of the Transformed Phenotypes Induced by the c-Ha-ras Oncogene", (1990) Mol. Cell. Biol. 10:1545-1555.
Sepp-Lorenzino, Laura, et al., "Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells", (1996) Oncogene, 12, 1679-1687.
Soldatenkov, MD, V.A., et al., "Inhibition of Raf-1 Protein Kinase by Antisense Phosphorothioate Oligodeoxyribonucleotide Is Associated with Sensitization of Human Laryngeal Squamous Carcinoma Cells to Gamma Radiation", (1997) The Cancer Journal from Scientific American 3, 13-20.
Suy, Simeng, et al., "Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells", (1997) Oncogene, 15, 53-61.
Vaughn, James P., et al., "Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides", (1996) Nucleic Acids Res., 24, 4558-4564.
Chang Esther H.
Pirollo Kathleen F.
Brusca John S.
Shibuya Mark L.
LandOfFree
Compositions and methods for reducing radiation and drug resista does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for reducing radiation and drug resista, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for reducing radiation and drug resista will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-519494